Novateor Research Laboratories Ltd
₹ 32.0
-2.59%
31 Aug
- close price
About
Incorporated in 2011, Novateor Research Laboratories Ltd is in the business of Oral Care and Personal Care products.[1]
Key Points
- Market Cap ₹ 19.4 Cr.
- Current Price ₹ 32.0
- High / Low ₹ 34.5 / 20.1
- Stock P/E 194
- Book Value ₹ 19.0
- Dividend Yield 0.00 %
- ROCE 1.67 %
- ROE 0.91 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 0.72% over last 3 years.
- Company has high debtors of 269 days.
- Promoter holding has decreased over last 3 years: -10.1%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | 0.10 | 0.14 | 0.09 | 0.41 | 0.39 | 0.19 | 0.74 | 1.26 | 1.21 | 2.78 | 3.83 | |
| 0.02 | 0.11 | 0.08 | 0.04 | 0.13 | 0.53 | 0.52 | 0.92 | 1.60 | 1.54 | 2.92 | 3.93 | |
| Operating Profit | 0.00 | -0.01 | 0.06 | 0.05 | 0.28 | -0.14 | -0.33 | -0.18 | -0.34 | -0.33 | -0.14 | -0.10 |
| OPM % | 0.00% | -10.00% | 42.86% | 55.56% | 68.29% | -35.90% | -173.68% | -24.32% | -26.98% | -27.27% | -5.04% | -2.61% |
| 0.00 | 0.01 | 0.02 | 0.03 | 0.11 | 0.27 | 0.44 | 0.01 | 0.49 | 0.49 | 0.48 | 0.49 | |
| Interest | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.02 | 0.03 | 0.07 | 0.09 |
| Depreciation | 0.00 | 0.00 | 0.07 | 0.07 | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 | 0.08 | 0.16 | 0.19 |
| Profit before tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 0.02 | 0.01 | -0.26 | 0.04 | 0.05 | 0.11 | 0.11 |
| Tax % | 24.14% | 150.00% | 0.00% | -11.54% | 0.00% | 40.00% | 27.27% | 18.18% | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | -0.01 | 0.01 | -0.23 | 0.04 | 0.03 | 0.08 | 0.10 | |
| EPS in Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.74 | -0.02 | 0.02 | -0.48 | 0.08 | 0.06 | 0.17 | 0.17 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 44% |
| 5 Years: | 82% |
| 3 Years: | 45% |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 58% |
| 3 Years: | 36% |
| TTM: | 25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 40% |
| 3 Years: | 0% |
| 1 Year: | 2% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 0.05 | 0.05 | 2.96 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 6.05 |
| Reserves | 0.88 | 0.88 | 0.88 | 0.88 | 1.11 | 3.73 | 3.74 | 3.01 | 3.04 | 3.93 | 5.71 | 5.45 |
| 0.75 | 0.76 | 0.87 | 0.82 | 0.01 | 0.00 | 0.24 | 0.24 | 0.84 | 1.11 | 0.91 | 1.02 | |
| 0.11 | 0.15 | 0.10 | 0.09 | 0.24 | 0.23 | 0.17 | 0.06 | 0.24 | 0.59 | 1.16 | 1.74 | |
| Total Liabilities | 1.79 | 1.84 | 1.90 | 1.84 | 4.32 | 8.79 | 8.98 | 8.14 | 8.95 | 10.46 | 12.61 | 14.26 |
| 1.59 | 1.64 | 1.66 | 1.59 | 3.55 | 3.45 | 3.36 | 1.94 | 1.78 | 2.43 | 3.41 | 3.24 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.44 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| 0.19 | 0.19 | 0.23 | 0.24 | 0.76 | 5.33 | 5.61 | 6.19 | 6.73 | 7.58 | 9.19 | 11.01 | |
| Total Assets | 1.79 | 1.84 | 1.90 | 1.84 | 4.32 | 8.79 | 8.98 | 8.14 | 8.95 | 10.46 | 12.61 | 14.26 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.01 | 0.05 | -0.07 | -3.42 | -0.27 | -0.97 | -0.97 | -0.98 | -1.03 | -0.18 | |
| 0.00 | 0.00 | -0.01 | 0.00 | -1.96 | -0.10 | -0.09 | 0.91 | 0.13 | -0.25 | -0.22 | -0.50 | |
| 0.00 | 0.00 | 0.00 | -0.03 | 2.03 | 4.18 | 0.32 | -0.13 | 0.58 | 1.10 | 1.43 | 0.89 | |
| Net Cash Flow | 0.00 | 0.00 | -0.01 | 0.02 | 0.00 | 0.67 | -0.04 | -0.18 | -0.26 | -0.13 | 0.18 | 0.20 |
| Free Cash Flow | 0.00 | 0.00 | 0.00 | 0.05 | -2.03 | -3.52 | -0.36 | -0.06 | -1.33 | -1.72 | -1.73 | -0.20 |
| CFO/OP | 0% | 17% | 100% | 0% | 2,443% | 82% | 539% | 285% | 297% | 736% | 180% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365.00 | 219.00 | 182.50 | 243.33 | 133.54 | 233.97 | 384.21 | 212.09 | 202.78 | 337.85 | 271.78 | 268.75 |
| Inventory Days | 4,380.00 | 438.00 | 1,460.00 | 2,737.50 | 6,448.33 | 700.80 | 851.67 | 344.34 | 215.16 | 268.95 | 151.10 | 152.08 |
| Days Payable | 1,460.00 | 292.00 | 730.00 | 1,095.00 | 1,460.00 | 14.60 | 104.29 | 20.66 | 61.47 | 207.47 | 176.61 | 208.57 |
| Cash Conversion Cycle | 3,285.00 | 365.00 | 912.50 | 1,885.83 | 5,121.87 | 920.17 | 1,131.59 | 535.77 | 356.46 | 399.32 | 246.27 | 212.26 |
| Working Capital Days | 1,277.50 | 109.50 | 286.79 | 527.22 | 462.93 | 4,117.95 | 9,067.37 | 2,747.36 | 1,604.84 | 1,879.30 | 950.58 | 770.98 |
| ROCE % | 0.00% | 0.00% | 0.57% | 0.56% | 9.95% | 0.47% | 0.12% | 2.49% | 0.71% | 0.86% | 1.69% | 1.67% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Number of Permanent Employees employees |
|
||||||
| Number of Product Categories in Portfolio categories |
|||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Outcome for Outcome Of Board Meeting Of The Board Held On Thursday, September 03, 2026
- Board approved office shift subject to shareholder approval, auditor reappointments, and 15th AGM on 29 September 2026.
-
Board Meeting Intimation for Approval Of Agenda Related To Ensuing AGM And Other Businesses With The Permission Of Chairman
- Board meeting scheduled for 3 September 2026 to consider the ensuing Annual Meeting.
-
The Company Has Entered Into Marketer And Manufacturing Agreement With Smart Laboratories Private Limited
- Novateor signed marketer-manufacturer agreement; received 10,000-unit order worth ₹8.40 lakh, to execute within one month.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Filed Regulation 74(5) certificate for quarter ended June 30, 2026; no demat or remat requests received.
-
Launch Of New Product- Smiloshine Herbafresh Toothpaste Formulated With 8 Herbs, 6 Grams Sachet
- Novateor launched SmiloShine Herbafresh Toothpaste 6g sachet on 15 June 2026 for domestic and international markets.
Business Overview:[1]
a) NRLL develops FDA-approved personal care products for clinical and commercial purposes.
b) It’s current Teeth Whitening products
are sold under the brand name Smile Shine
c) The company manufactures 3 different variants of Teeth Whitening Strips, Teeth White
Toothpaste and brush, Kids Toothpaste and
tongue cleaner, Teeth Whitening Gel, Power
Brush.
d) It intends to expand its business in cosmetics, various health care pharma products in the near future
e) The company’s customer base consists of Dentists as well as Cosmetic Parlors